Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 77 - 102
Published: Oct. 25, 2024
Language: Английский
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Feb. 15, 2023
Abstract As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of immunotherapy recent years. They extraordinary antitumor potential and prospects for clinical application. Immune checkpoint inhibitors (ICIs), which are efficacious tumor patients, become pioneer drugs since they were incorporated into practice. In addition, that infiltrated tissues found to be state exhaustion or anergy, there is upregulation many immune checkpoints (ICs) on their surface, suggesting similar ability respond ICIs as traditional effector T cells. Studies shown targeting ICs can reverse dysfunctional microenvironment (TME) exert effects by improving γδT-cell proliferation activation enhancing cytotoxicity. Clarification functional TME mechanisms underlying interaction with will solidify combined good treatment option.
Language: Английский
Citations
73
Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)
Published: Jan. 16, 2024
Abstract As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4 + cells, CD8 natural killer (NK) regulatory cells (Tregs), tumor-infiltrating lymphocytes (TILs). TIGIT has been associated NK exhaustion in vivo individuals various cancers. It not only modulates survival but also mediates exhaustion. the primary ligand of humans, CD155 may be main target for immunotherapy due to its interaction TIGIT. found that anti-programmed death protein 1 (PD-1) treatment response cancer correlated Anti-TIGIT alone combination anti-PD-1 agents have tested immunotherapy. Although two clinical studies advanced lung had positive results, TIGIT-targeted antibody, tiragolumab, recently failed new trials. In this review, we highlight current developments discuss characteristics functions
Language: Английский
Citations
32
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: Aug. 9, 2024
The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. role immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD ligand-1 antibodies, has become increasingly pivotal in treatment advanced perioperative GI Currently, anti-PD-1 plus chemotherapy is considered as first-line regimen unselected gastric/gastroesophageal junction adenocarcinoma (G/GEJC), mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC), esophageal (EC). In addition, encouraging performance claudin18.2-redirected chimeric antigen receptor T-cell (CAR-T) therapy later-line cancers brings new hope cell solid tumour treatment. Nevertheless, remains yet precise, researchers are dedicated to further maximising optimising efficacy. This review summarises important research, latest progress, future directions including EC, G/GEJC, CRC.
Language: Английский
Citations
20
Nature Cancer, Journal Year: 2024, Volume and Issue: 5(8), P. 1145 - 1157
Published: July 26, 2024
Language: Английский
Citations
9
Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12
Published: May 17, 2022
The in-depth characterization of cross-talk between tumor cells and T in solid hematological malignancies will have to be considered develop new therapeutical strategies concerning the reactivation maintenance patient-specific antitumor responses within patient microenvironment. Activation immune depends on a delicate balance activating inhibitory signals mediated by different receptors. cell immunoreceptor with immunoglobulin ITIM domain (TIGIT) is an receptor expressed regulatory (Tregs), activated cells, natural killer (NK) cells. TIGIT pathway regulates cell-mediated recognition vivo vitro represents exciting target for checkpoint blockade immunotherapy. as monotherapy or combination other inhibitor receptors drugs emerging clinical trials patients cancer. purpose this review update role cancer progression, looking at pathways that are often upregulated possible therapeutic avoid aggressiveness, drug resistance, treatment side effects. However, first part, we overviewed checkpoints immunoediting, structure ligands, summarized key express TIGIT.
Language: Английский
Citations
32
Biochemical Pharmacology, Journal Year: 2023, Volume and Issue: 209, P. 115445 - 115445
Published: Feb. 2, 2023
Language: Английский
Citations
21
OncoImmunology, Journal Year: 2024, Volume and Issue: 13(1)
Published: May 9, 2024
Immune exhaustion is a hallmark of ovarian cancer. Using multiparametric flow cytometry, the study aimed to analyze protein expression novel immunological targets on CD3
Language: Английский
Citations
6
Biomedicines, Journal Year: 2022, Volume and Issue: 10(11), P. 2826 - 2826
Published: Nov. 5, 2022
Ovarian cancer has the highest mortality rate among gynecologic malignancies. The main treatment options are surgical removal of tumor and chemotherapy. Cancer been revolutionized by immunotherapy, which developed explosively over past two decades. Clinical anticancer strategies used in immunotherapy include therapies based on inhibition PD-1, PD-L1 or CTLA-4. Despite encouraging results, a large proportion patients resistant to these eventually develop resistance. It is important perform research that will focus other immune checkpoint inhibitors. aim review was analyze studies considering expression TIM-3 LAG-3 ovarian microenvironment for includes antibodies directed against LAG-3. As data showed, described checkpoints shown different ways. Higher associated with more advanced stage. Both were co-expressed PD-1 studies. effect progression-free survival and/or overall inconclusive certainly requires further study. Co-expression prompts combination using anti-LAG-3 anti-TIM-3. Research checkpoints, especially LAG-3, should be developed.
Language: Английский
Citations
27
Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: Aug. 13, 2024
Although γδ T cells are known to participate in immune dysregulation solid tumors, their relevance human microsatellite-stable (MSS) colorectal cancer (CRC) is still undefined. Here, using integrated gene expression analysis and cell receptor sequencing, we characterized MSS CRC, with a focus on Vδ1 + cells. We identified Vδ1+ shared motifs the third complementarity-determining region of δ-chain, reflective antigen recognition. Changes protein levels suggested dysfunctional effector state distinct from microsatellite-instable (MSI). Interaction highlighted an immunosuppressive role fibroblasts CRC via TIGIT-NECTIN2 axis. Blocking this pathway TIGIT antibody partially restored cytotoxicity phenotype. These results define operative CRC. less well-studied. single-cell RNA-sequencing, authors identify subset, which functionally impaired interaction.
Language: Английский
Citations
5
Journal of Leukocyte Biology, Journal Year: 2022, Volume and Issue: 112(6), P. 1669 - 1676
Published: Aug. 24, 2022
Abstract T lymphocytes are the key protective contributors in chronic infection and tumor, but experience exhaustion by persistent antigen stimulation. As an unconventional lineage of cells, γδ cells can rapidly response to varied infectious tumor challenges a non-MHC-restricted manner play roles immune surveillance via pleiotropic effector functions, showing promising as candidates for cellular immunotherapy. Activated also acquire signature with elevated expression checkpoints, such PD-1, decreased cytokine production, functional impairment. However, features distinct from conventional αβ cells. Here, we review researches regarding characteristics, heterogeneity, mechanisms cell exhaustion. These studies provide insights into combined strategies overcome enhance antitumor immunity. Summary sentence: Review provides cell-based
Language: Английский
Citations
19